In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Nivalis Therapeutics Inc. (NASDAQ:NVLS) reported that Flynn James E has picked up 3,732,414 of common stock as of 2017-04-25.
The acquisition brings the aggregate amount owned by Flynn James E to a total of 3,732,414 representing less than 23.84% stake in the company.
For those not familiar with the company, Nivalis Therapeutics, Inc. is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration. The Company’s S-nitrosoglutathione reductase (GSNOR) inhibitors selectively target GSNOR. Depleted levels of S-nitrosoglutathione (GSNO) have been associated with CF, asthma, inflammatory bowel diseases and certain cardiovascular diseases. The Company’s lead product candidate, cavosonstat (N91115), is a small molecule inhibitor of GSNOR. cavosonstat is a pill that is in two Phase II clinical trials intended to address a defect in CF transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. Its preclinical studies have shown that cavosonstat is a selective and reversible inhibitor of GSNOR.
A glance at Nivalis Therapeutics Inc. (NASDAQ:NVLS)’s key stats reveals a current market capitalization of 30.58 Million based on 15.66 Million shares outstanding and a price at last close of $2.10 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-12-02, Carruthers picked up 24,000 at a purchase price of $2.09. This brings their total holding to 24,000 as of the date of the filing.
On the sell side, the most recent transaction saw Rodman unload 6,687 shares at a sale price of 2.27. This brings their total holding to 11,368.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Nivalis Therapeutics Inc. (NASDAQ:NVLS) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.